Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
271. |
ECCT/21/09/08 | GBT133_Inclacumab Open-Label An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial |
Principal Investigator(s) 1. Fredrick Sirwa Chite 2. Bernhards Ragama Ogutu 3. Videlis N Nduba 4. Prof Jessie N Githanga Site(s) in Kenya 1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 2. KEMRI/CRDR (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Gertrude’s Children’s Hospital. (Nairobi City county) 5. Strathmore University Medical Centre (Nairobi City county) |
22-03-2022 |
View |
272. |
ECCT/21/09/06 | The PrEDIRA Study PILOTING HIV PRE-EXPOSURE PROPHYLAXIS (PREP) INTEGRATION INTO SERVICES FOR EARLY PREGNANCY LOSS |
Principal Investigator(s) 1. Prof. Elizabeth Bukusi 2. Dr. Nelly Mugo 3. Renee Heffron Site(s) in Kenya 1. KEMRI RCTP (Kisumu county) 2. PARTNERS IN HEALTH RESEARCH AND DEVELOPMENT - THIKA (Kiambu county) |
10-11-2021 |
View |
273. |
ECCT/21/09/04 | Recombinant COVID-19 Vaccine A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells) for the prevention of COVID-19 in adults aged 18 years and older |
Principal Investigator(s) 1. Sylvester Kimaiyo Site(s) in Kenya 1. KAVI-Institute of Clinical Research (Nairobi City county) 2. Moi Teaching and Referral Hospital (Uasin Gishu county) 3. Kenya Medical Research Institute, Kilifi (Kilifi county) |
17-09-2021 |
View |
274. |
ECCT/21/09/03 | Women TDF/FTC Benchmark Study Pharmacology of TDF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender Women |
Principal Investigator(s) 1. Nelly Mugo Site(s) in Kenya KEMRI-CCR PHRD (THIKA) PROJECT |
19-12-2021 |
View |
275. |
ECCT/21/09/02 | PrEDIRA - 2 Piloting HIV Pre-exposure Prophylaxis (PrEP) Integration into Services for Early Pregnancy Loss |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya 1. KEMRI-CCR PHRD THIKA - Thika, Nairobi, Murang\'a, and their environs (Kiambu county) 2. Kisumu clinical trial site - Kisumu and its enrvirons (Kisumu county) 3. Mariestopes - Nairobi (Nairobi City county) |
23-01-2022 |
View |
276. |
ECCT/21/09/01 | Kuwa Free! - Live free! Co-benefits of co-delivery of long-acting antiretrovirals and contraceptives |
Principal Investigator(s) 1. Rena Patel 2. Edwin Were Site(s) in Kenya Moi Teaching and Referral Hospital |
16-09-2022 |
View |
277. |
ECCT/21/08/02 | IPrEP Men\'s Study IPrEP Men’s Study: Expanding the reach of prevention for men in Kisumu, Kenya |
Principal Investigator(s) 1. Kawango Agot 2. Wafaa El-Sadr Site(s) in Kenya Kisumu Impact Research and Development Organization (K-IRDO) CRS |
11-11-2021 |
View |
278. |
ECCT/21/08/01 | CARES Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety,and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine From Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa. |
Principal Investigator(s) 1. JOSPHAT KOSGEI Site(s) in Kenya 1. AMPATH Eldoret (Uasin Gishu county) 2. Aghakhan University (Nairobi City county) 3. Kericho KEMRI WRP CRC site (Kericho county) |
30-11-2021 |
View |
279. |
ECCT/21/07/06 | GBT132_Inclacumab-Ps 3 Trial A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises. |
Principal Investigator(s) 1. Fredrick Asirwa Chite 2. Videlis N Nduba 3. Bernhards Ragama Ogutu Site(s) in Kenya 1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 2. KEMRI/CRDR (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Strathmore University Medical Centre (Nairobi City county) |
09-11-2021 |
View |
280. |
ECCT/21/07/05 | CARES A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine from Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa |
Principal Investigator(s) 1. Dr Reena Shah Site(s) in Kenya 1. Aga Khan University Hospital Nairobi (Nairobi City county) 2. KEMRI Walter Reed Project (Kericho county) 3. Moi University Clinical Research Centre (Uasin Gishu county) |
09-11-2021 |
View |